Skip to content
value.today

Lengo Therapeutics, Inc.

🇺🇸 Menlo Park, California, USAPharmaceuticalsFounded 2019
Total raised
$18 M
1 round on record
Latest round
$18 M
Mar 2020
First round on record
Mar 2020
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Lengo Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2020$18 MNo. 1$10 to $50 million

Lengo Therapeutics, Inc.: Raise no. 1, Mar 2020

Investors in this round

4 investors had bought by the notice of Apr 30, 2021: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Anna Chen · Executive Officer · Treasurer and Secretary
  • Daniel Estes, Ph.D. · Executive Officer, Director · President
  • Helen Jenkins · Executive Officer, Director · Chief Executive Officer
  • Steve Bailey · Executive Officer · Vice President
  • David Johnson · Director
  • Roger Ulrich, Ph.D. · Director
  • Tracy Saxton, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Helen Jenkins, Chief Executive Officer. Newest notice filed Apr 30, 2021 (1 amendment). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Lengo Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2021).

    SEC Form D · Apr 2021

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2021

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Lengo Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Lengo Therapeutics, Inc.
NameRoleNamed in
Anna ChenTreasurer and SecretaryApr 2021
Daniel Estes, Ph.D.PresidentApr 2021
Helen JenkinsChief Executive OfficerApr 2021
Steve BaileyVice PresidentApr 2021
Tracy Saxton, Ph.D.Chief Executive OfficerApr 2020
Daniel Estes, Ph.D.PresidentApr 2021
David JohnsonDirectorApr 2021
Helen JenkinsChief Executive OfficerApr 2021
Roger Ulrich, Ph.D.DirectorApr 2021
Tracy Saxton, Ph.D.DirectorApr 2021